# Asure Software Inc: financial statements, quarterly ASUR · Nasdaq · CIK 884144 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/asur.md) · [Financials](/companies/asur/financials.md) · [Filings](/companies/asur/filings.md) · [Insiders](/companies/asur/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/asur/financials.md?period=annual). ## Income statement | Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [26.3 d](/filings/0000884144-24-000022.md) | [31.7](/filings/0000884144-25-000064.md) | [28.0](/filings/0000884144-25-000088.md) | [29.3](/filings/0001628280-25-047524.md) | not reported | [34.9](/filings/0001628280-26-028860.md) | [30.1](/filings/0001628280-26-051066.md) | [36.3](/filings/0001628280-26-068268.md) | not reported | [42.8](/filings/0001628280-26-028860.md) | [37.1](/filings/0001628280-26-051066.md) | [40.0](/filings/0001628280-26-068268.md) | | Cost of revenue | $m | [8.4 d](/filings/0000884144-25-000012.md) | [9.0](/filings/0000884144-25-000064.md) | [9.2](/filings/0000884144-25-000088.md) | [9.6](/filings/0001628280-25-047524.md) | [9.9 d](/filings/0001628280-26-012270.md) | [10.2](/filings/0001628280-26-028860.md) | [10.2](/filings/0001628280-26-051066.md) | [12.7](/filings/0001628280-26-068268.md) | [12.6 d](/filings/0001628280-26-012270.md) | [12.3](/filings/0001628280-26-028860.md) | [12.1](/filings/0001628280-26-051066.md) | [12.2](/filings/0001628280-26-068268.md) | | Gross profit | $m | [17.8 d](/filings/0000884144-25-000012.md) | [22.6](/filings/0000884144-25-000064.md) | [18.9](/filings/0000884144-25-000088.md) | [19.7](/filings/0001628280-25-047524.md) | [20.9 d](/filings/0001628280-26-012270.md) | [24.6](/filings/0001628280-26-028860.md) | [19.9](/filings/0001628280-26-051066.md) | [23.5](/filings/0001628280-26-068268.md) | [26.7 d](/filings/0001628280-26-012270.md) | [30.5](/filings/0001628280-26-028860.md) | [25.1](/filings/0001628280-26-051066.md) | [27.8](/filings/0001628280-26-068268.md) | | Research and development | $m | [1.7 d](/filings/0000884144-25-000012.md) | [1.8](/filings/0000884144-25-000064.md) | [2.0](/filings/0000884144-25-000088.md) | [2.0](/filings/0001628280-25-047524.md) | [2.1 d](/filings/0001628280-26-012270.md) | [2.0](/filings/0001628280-26-028860.md) | [1.3](/filings/0001628280-26-051066.md) | [1.6](/filings/0001628280-26-068268.md) | [0.6 d](/filings/0001628280-26-012270.md) | [1.7](/filings/0001628280-26-028860.md) | [1.6](/filings/0001628280-26-051066.md) | [1.7](/filings/0001628280-26-068268.md) | | Selling, general and administrative | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating income | $m | [(3.8) d](/filings/0000884144-25-000012.md) | [(0.4)](/filings/0000884144-25-000064.md) | [(4.2)](/filings/0000884144-25-000088.md) | [(3.6)](/filings/0001628280-25-047524.md) | [(2.5) d](/filings/0001628280-26-012270.md) | [(2.0)](/filings/0001628280-26-028860.md) | [(4.7)](/filings/0001628280-26-051066.md) | [(3.5)](/filings/0001628280-26-068268.md) | [1.8 d](/filings/0001628280-26-012270.md) | [2.3](/filings/0001628280-26-028860.md) | [(2.4)](/filings/0001628280-26-051066.md) | [0.5](/filings/0001628280-26-068268.md) | | Interest expense | $m | [0.3 d](/filings/0000884144-25-000012.md) | [0.2](/filings/0000884144-25-000064.md) | [0.2](/filings/0000884144-25-000088.md) | [0.3](/filings/0001628280-25-047524.md) | [0.4 d](/filings/0001628280-26-012270.md) | [0.5](/filings/0001628280-26-028860.md) | [0.8](/filings/0001628280-26-051066.md) | [2.0](/filings/0001628280-26-068268.md) | [1.8 d](/filings/0001628280-26-012270.md) | [1.7](/filings/0001628280-26-028860.md) | [1.8](/filings/0001628280-26-051066.md) | [1.8](/filings/0001628280-26-068268.md) | | Income tax | $m | [(0.2) d](/filings/0000884144-25-000012.md) | [0.0](/filings/0000884144-25-000064.md) | [0.2](/filings/0000884144-25-000088.md) | [0.2](/filings/0001628280-25-047524.md) | [0.5 d](/filings/0001628280-26-012270.md) | [0.3](/filings/0001628280-26-028860.md) | [0.8](/filings/0001628280-26-051066.md) | [0.4](/filings/0001628280-26-068268.md) | [(0.8) d](/filings/0001628280-26-012270.md) | [0.1](/filings/0001628280-26-028860.md) | [0.5](/filings/0001628280-26-051066.md) | [(0.5)](/filings/0001628280-26-068268.md) | | Net income | $m | [(3.6) d](/filings/0000884144-25-000012.md) | [(0.3)](/filings/0001628280-25-047524.md) | [(4.4)](/filings/0001628280-25-047524.md) | [(3.9)](/filings/0001628280-25-047524.md) | [(3.2) d](/filings/0001628280-26-012270.md) | [(2.4)](/filings/0001628280-26-068268.md) | [(6.1)](/filings/0001628280-26-068268.md) | [(5.4)](/filings/0001628280-26-068268.md) | [0.8 d](/filings/0001628280-26-012270.md) | [0.6](/filings/0001628280-26-068268.md) | [(4.4)](/filings/0001628280-26-068268.md) | [(0.6)](/filings/0001628280-26-068268.md) | | Diluted EPS | $ per share | not reported | [(0.01)](/filings/0000884144-25-000064.md) | [(0.17)](/filings/0000884144-25-000088.md) | [(0.15)](/filings/0001628280-25-047524.md) | not reported | [(0.09)](/filings/0001628280-26-028860.md) | [(0.22)](/filings/0001628280-26-051066.md) | [(0.19)](/filings/0001628280-26-068268.md) | not reported | [0.02](/filings/0001628280-26-028860.md) | [(0.15)](/filings/0001628280-26-051066.md) | [(0.02)](/filings/0001628280-26-068268.md) | | Basic EPS | $ per share | not reported | [(0.01)](/filings/0000884144-25-000064.md) | [(0.17)](/filings/0000884144-25-000088.md) | [(0.15)](/filings/0001628280-25-047524.md) | not reported | [(0.09)](/filings/0001628280-26-028860.md) | [(0.22)](/filings/0001628280-26-051066.md) | [(0.19)](/filings/0001628280-26-068268.md) | not reported | [0.02](/filings/0001628280-26-028860.md) | [(0.15)](/filings/0001628280-26-051066.md) | [(0.02)](/filings/0001628280-26-068268.md) | - Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax - Cost of revenue: us-gaap:CostOfGoodsAndServicesSold - Gross profit: us-gaap:GrossProfit - Research and development: us-gaap:ResearchAndDevelopmentExpense - Selling, general and administrative: not reported - Operating income: us-gaap:OperatingIncomeLoss - Interest expense: us-gaap:InterestExpenseNonoperating - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $m | [30.3](/filings/0000884144-25-000012.md) | [23.2](/filings/0000884144-25-000064.md) | [20.7](/filings/0000884144-25-000088.md) | [11.2](/filings/0001628280-25-047524.md) | [21.4](/filings/0001628280-26-012270.md) | [14.1](/filings/0001628280-26-028860.md) | [66.0](/filings/0001628280-26-051066.md) | [21.5](/filings/0001628280-26-068268.md) | [25.2](/filings/0001628280-26-068268.md) | [19.2](/filings/0001628280-26-028860.md) | [19.7](/filings/0001628280-26-051066.md) | [16.8](/filings/0001628280-26-068268.md) | | Current assets | $m | [267](/filings/0000884144-25-000012.md) | [282](/filings/0000884144-24-000039.md) | [232](/filings/0000884144-24-000053.md) | [227](/filings/0000884144-24-000064.md) | [237](/filings/0001628280-26-012270.md) | [293](/filings/0000884144-25-000064.md) | [300](/filings/0000884144-25-000088.md) | [193](/filings/0001628280-25-047524.md) | [278](/filings/0001628280-26-068268.md) | [259](/filings/0001628280-26-028860.md) | [222](/filings/0001628280-26-051066.md) | [237](/filings/0001628280-26-068268.md) | | Total assets | $m | [444](/filings/0000884144-25-000012.md) | [469](/filings/0000884144-24-000039.md) | [420](/filings/0000884144-24-000053.md) | [428](/filings/0000884144-24-000064.md) | [437](/filings/0001628280-26-012270.md) | [499](/filings/0000884144-25-000064.md) | [506](/filings/0000884144-25-000088.md) | [447](/filings/0001628280-25-047524.md) | [531](/filings/0001628280-26-068268.md) | [519](/filings/0001628280-26-028860.md) | [478](/filings/0001628280-26-051066.md) | [491](/filings/0001628280-26-068268.md) | | Current liabilities | $m | [241](/filings/0000884144-25-000012.md) | [258](/filings/0000884144-24-000039.md) | [209](/filings/0000884144-24-000053.md) | [212](/filings/0000884144-24-000064.md) | [224](/filings/0001628280-26-012270.md) | [284](/filings/0000884144-25-000064.md) | [235](/filings/0000884144-25-000088.md) | [178](/filings/0001628280-25-047524.md) | [260](/filings/0001628280-26-068268.md) | [246](/filings/0001628280-26-028860.md) | [208](/filings/0001628280-26-051066.md) | [226](/filings/0001628280-26-068268.md) | | Total liabilities | $m | [252](/filings/0000884144-25-000012.md) | [272](/filings/0000884144-24-000039.md) | [225](/filings/0000884144-24-000053.md) | [229](/filings/0000884144-24-000064.md) | [239](/filings/0001628280-26-012270.md) | [301](/filings/0000884144-25-000064.md) | [311](/filings/0000884144-25-000088.md) | [254](/filings/0001628280-25-047524.md) | [334](/filings/0001628280-26-068268.md) | [319](/filings/0001628280-26-028860.md) | [280](/filings/0001628280-26-051066.md) | [293](/filings/0001628280-26-068268.md) | | Long-term debt | $m | [4.3](/filings/0000884144-25-000012.md) | [5.3](/filings/0000884144-24-000039.md) | [6.0](/filings/0000884144-24-000053.md) | [7.5](/filings/0000884144-24-000064.md) | [5.7](/filings/0001628280-26-012270.md) | [6.2](/filings/0000884144-25-000064.md) | [64.4](/filings/0000884144-25-000088.md) | [64.2](/filings/0001628280-25-047524.md) | [63.3](/filings/0001628280-26-068268.md) | [62.3](/filings/0001628280-26-028860.md) | [62.2](/filings/0001628280-26-051066.md) | [59.4](/filings/0001628280-26-068268.md) | | Current portion of debt | $m | [0.0](/filings/0000884144-25-000012.md) | [0.0](/filings/0000884144-24-000039.md) | [0.0](/filings/0000884144-24-000053.md) | [0.0](/filings/0000884144-24-000064.md) | [7.0](/filings/0001628280-26-012270.md) | [7.9](/filings/0000884144-25-000064.md) | [3.0](/filings/0000884144-25-000088.md) | [6.2](/filings/0001628280-25-047524.md) | [4.3](/filings/0001628280-26-068268.md) | [6.5](/filings/0001628280-26-028860.md) | [6.7](/filings/0001628280-26-051066.md) | [5.3](/filings/0001628280-26-068268.md) | | Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Shareholders' equity | $m | [192](/filings/0000884144-25-000012.md) | [198](/filings/0000884144-24-000039.md) | [196](/filings/0000884144-24-000053.md) | [199](/filings/0000884144-24-000064.md) | [197](/filings/0001628280-26-012270.md) | [198](/filings/0000884144-25-000064.md) | [194](/filings/0000884144-25-000088.md) | [193](/filings/0001628280-25-047524.md) | [198](/filings/0001628280-26-068268.md) | [200](/filings/0001628280-26-028860.md) | [198](/filings/0001628280-26-051066.md) | [197](/filings/0001628280-26-068268.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Long-term debt: us-gaap:LongTermDebtNoncurrent - Current portion of debt: us-gaap:LongTermDebtCurrent - Short-term borrowings: not reported - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $m | [7.1 d](/filings/0000884144-25-000012.md) | [(3.9)](/filings/0000884144-25-000064.md) | [2.2 d](/filings/0000884144-25-000088.md) | [1.3 d](/filings/0001628280-25-047524.md) | [9.8 d](/filings/0001628280-26-012270.md) | [2.0](/filings/0001628280-26-028860.md) | [3.2 d](/filings/0001628280-26-051066.md) | [5.8 d](/filings/0001628280-26-068268.md) | [11.3 d](/filings/0001628280-26-012270.md) | [2.7](/filings/0001628280-26-028860.md) | [4.5 d](/filings/0001628280-26-051066.md) | [5.6 d](/filings/0001628280-26-068268.md) | | Capital expenditure | $m | [0.2 d](/filings/0000884144-25-000012.md) | [0.2](/filings/0000884144-25-000064.md) | [0.1 d](/filings/0000884144-25-000088.md) | [0.2 d](/filings/0001628280-25-047524.md) | [0.1 d](/filings/0001628280-26-012270.md) | [0.2](/filings/0001628280-26-028860.md) | [0.2 d](/filings/0001628280-26-051066.md) | [0.1 d](/filings/0001628280-26-068268.md) | [0.3 d](/filings/0001628280-26-012270.md) | [0.2](/filings/0001628280-26-028860.md) | [0.3 d](/filings/0001628280-26-051066.md) | [0.1 d](/filings/0001628280-26-068268.md) | | Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment - Share repurchases: not reported ## Shares | Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [21.0](/filings/0000884144-24-000039.md) | [20.7](/filings/0000884144-24-000053.md) | [22.6](/filings/0000884144-24-000064.md) | [25.3](/filings/0000884144-25-000064.md) | [25.8](/filings/0000884144-25-000088.md) | [26.4](/filings/0001628280-25-047524.md) | [27.0](/filings/0001628280-26-028860.md) | [27.2](/filings/0001628280-26-051066.md) | [27.6](/filings/0001628280-26-068268.md) | [28.9](/filings/0001628280-26-028860.md) | [28.7](/filings/0001628280-26-051066.md) | [28.9](/filings/0001628280-26-068268.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Shares outstanding: 30,169,748 at 2026-10-28, from the cover of the [10-Q filed 2026-10-29](/filings/0001628280-26-068268.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 29, 2026, 18:27 ET. No prices; not investment advice.